Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map

被引:9
作者
Casas-Maldonado, Francisco [1 ]
Alvarez-Gutierrez, Francisco-Javier [2 ]
Blanco-Aparicio, Marina [3 ]
Domingo-Ribas, Christian [4 ,5 ]
Cisneros-Serrano, Carolina [6 ,7 ]
Soto-Campos, Gregorio [8 ]
Roman-Bernal, Berta [9 ]
Gonzalez-Barcala, Francisco-Javier [10 ,11 ,12 ,13 ]
机构
[1] Hosp Univ Clin San Cecilio, Serv Neumol, Granada, Spain
[2] Hosp Univ Virgen Rocio, Serv Neumol, Seville, Spain
[3] Hosp Univ A Coruna, Serv Neumol, La Coruna, Spain
[4] Corporacio Sanit Parc Tauli, Servei Pneumol, Barcelona, Spain
[5] Univ Autonoma Barcelona UAB, Dept Med, Barcelona, Spain
[6] Hosp Univ La Princesa, Serv Neumol, Madrid, Spain
[7] Fundac Invest Biomed La Princesa, Madrid, Spain
[8] Hosp Univ Jerez, Serv Neumol & Alergia, Cadiz, Spain
[9] Hosp Dr Jose Molina Orosa, Neumol, Las Palmas Gran Canaria, Spain
[10] Univ Santiago de Compostela, Hosp Clin, Serv Neumol, Rua Choupana S-N, Santiago De Compostela 15706, A Coruna, Spain
[11] Univ Santiago de Compostela, Dept Med, Santiago De Compostela, A Coruna, Spain
[12] Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
[13] Grp Translat Res Airway Dis FIDIS, Santiago De Compostela, A Coruna, Spain
关键词
Severe asthma; monoclonal antibodies; Mepolizumab; Dupilumab; Omalizumab; Reslizumab; Benralizumab; PREVALENCE; EXACERBATIONS; DEFINITION; GUIDELINES; THERAPY; UNITS; TIME;
D O I
10.1080/02770903.2021.1978483
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments. Objective To evaluate the proportion of patients with SUA treated with mABs in Spain, and to analyze some of the factors that could determine these prescription patterns. Methods An analysis was performed on the data provided from the Hospitals National Health System (NHS) 2018 catalogue where Chest Diseases Department and a Hospital Pharmacy were available. Random sampling was performed to determine the sample size, stratifying proportionally by geographic area and hospital level. Characteristics of the participating sites, as well as the prescribing of mABs were collected, which included geographic area, hospital levels, prescribing medical specialities, types of clinics, and mABs prescribed. Results Data from 90 hospitals were analyzed (Response rate 64.3%). Level 4 hospitals, the Canary Islands geographical area, and the presence of a high complexity Asthma Healthcare Unit (ACU) were associated with a higher probability that the SUA was treated with mABs. Conclusion The map of the prescribing of mABs for SUA in Spain shows a significant variation by geographic area, hospital level, type of clinic, and the accreditation level of the ACUs. At the current time, there appears to be significant under-prescribing of these treatments.
引用
收藏
页码:1997 / 2007
页数:11
相关论文
共 50 条
[41]   Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy [J].
Corren, Jonathan ;
Ambrose, Christopher S. ;
Salapa, Kinga ;
Roseti, Stephanie L. ;
Griffiths, Janet M. ;
Parnes, Jane R. ;
Colice, Gene .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (12) :4334-+
[42]   Severe uncontrolled asthma in patients over 75 years old: Treatment with omalizumab [J].
Romand, P. ;
Kelkel, E. ;
Saint-Raymond, C. ;
Glas, N. ;
Caillaud, D. ;
Devouassoux, G. .
REVUE DES MALADIES RESPIRATOIRES, 2016, 33 (05) :397-400
[43]   Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan [J].
Nagase, Hiroyuki ;
Adachi, Mitsuru ;
Matsunaga, Kazuto ;
Yoshida, Atsushi ;
Okoba, Tomoko ;
Hayashi, Nobuya ;
Emoto, Kahaku ;
Tohda, Yuji .
ALLERGOLOGY INTERNATIONAL, 2020, 69 (01) :53-60
[44]   Anti-Interleukin-5 Monoclonal Antibody to Treat Severe Eosinophilic Asthma [J].
Nair, Parameswaran .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) :1249-1251
[45]   Monoclonal antibody treatments for paediatric severe asthma-outcomes, attitudes, adherence [J].
Sheppard, M. ;
Kevat, A. ;
Owens, L. ;
Grey, M. .
RESPIROLOGY, 2022, 27 :108-108
[46]   Prevalence of Uncontrolled Severe Persistent Asthma in Pneumology and Allergy Hospital Units in Spain [J].
Quirce, S. ;
Plaza, V. ;
Picado, C. ;
Vennera, M. ;
Casafont, J. .
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2011, 21 (06) :466-471
[47]   RItA: The Italian severe/uncontrolled asthma registry [J].
Maio, S. ;
Baldacci, S. ;
Bresciani, M. ;
Simoni, M. ;
Latorre, M. ;
Murgia, N. ;
Spinozzi, F. ;
Braschi, M. ;
Antonicelli, L. ;
Brunetto, B. ;
Iacovacci, P. ;
Roazzi, P. ;
Pini, C. ;
Pata, M. ;
La Grasta, L. ;
Paggiaro, P. ;
Viegi, G. .
ALLERGY, 2018, 73 (03) :683-695
[48]   Guidelines for Severe Uncontrolled Asthma [J].
Cisneros Serrano, Carolina ;
Melero Moreno, Carlos ;
Almonacid Sanchez, Carlos ;
Perpina Tordera, Miguel ;
Picado Valles, Cesar ;
Martinez Moragon, Eva ;
Perez de Llano, Luis ;
Soto Campos, Jose Gregorio ;
Urrutia Landa, Isabel ;
Garcia Hernandez, Gloria .
ARCHIVOS DE BRONCONEUMOLOGIA, 2015, 51 (05) :235-246
[49]   Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison [J].
Cockle, Sarah M. ;
Stynes, Gillian ;
Gunsoy, Necdet B. ;
Parks, Daniel ;
Alfonso-Cristancho, Rafael ;
Wex, Jaro ;
Bradford, Eric S. ;
Albers, Frank C. ;
Willson, Jenny .
RESPIRATORY MEDICINE, 2017, 123 :140-148
[50]   Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma [J].
Drick, Nora ;
Milger, Katrin ;
Seeliger, Benjamin ;
Fuge, Jan ;
Korn, Stephanie ;
Buhl, Roland ;
Schuhmann, Maren ;
Herth, Felix ;
Kendziora, Benjamin ;
Behr, Juergen ;
Kneidinger, Nikolaus ;
Bergmann, Karl-Christian ;
Taube, Christian ;
Welte, Tobias ;
Suhling, Hendrik .
JOURNAL OF ASTHMA AND ALLERGY, 2020, 13 :605-614